Literature DB >> 14686493

Unusual association between increased bone resorption and presence of paroxysmal nocturnal hemoglobinuria phenotype in multiple myeloma.

Evangelos Terpos1, Michalis Samarkos, Christos Meletis, Effie Apostolidou, Maria Tsironi, Konstantinos Korovesis, Despina Mavrogianni, Nora Viniou, John Meletis.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) clones deficient in glycosylphosphatidylinositol-anchored molecules, including CD55 and CD59, have been previously described in patients with multiple myeloma (MM). The aim of this study was to investigate the possible association between existence of the PNH phenotype and myeloma bone disease. Forty-three patients with newly diagnosed MM were the subjects of the study. Radiographic evaluation of the skeleton was performed in all patients at diagnosis. The following biochemical markers were measured: bone resorption markers (tartrate-resistant acid phosphatase isoform 5b [TRACP-5b]and N-terminal cross-linking telopeptide of type-I collagen [NTX]), bone formation markers (bone alkaline phosphatase [bALP] and osteocalcin [OC]), osteoprotegerin (OPG), soluble receptor activator of nuclear factor KB ligand (sRANKL), and interleukin 6 (IL-6). Detection of CD55- and/or CD59-deficient red cell populations was performed after diagnosis. Patients with MM had elevated mean baseline NTX, TRACP-5b, sRANKL, and IL-6 levels compared with controls, whereas the mean values of bALP, OC, and OPG were significantly decreased. Four patients had no osteolytic lesions, whereas 8 patients had 1 to 3 lytic lesions, and 31 patients had more than 3 lytic lesions and/or pathologic fractures in the skeletal survey. CD55- and/or CD59-deficient red cell populations were observed in 56% of patients with MM. There was a strong correlation between the presence of PNH-like erythrocytes and increased bone resorption, as measured by NTX, TRACP-5b, and sRANKL/OPG ratio (P < .03, P < .02, and P < .02, respectively). There was also a significant correlation between PNH phenotype and severe bone disease (P < .02). These results suggest that there is a possible link between PNH phenotype and increased osteoclastic activity in MM owing to a potential effect of myeloma microenvironment on a preexisting PNH clone. Further studies are required for clarifying this phenomenon and investigating possible mechanisms of this unusual association.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14686493     DOI: 10.1007/BF02983560

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  31 in total

1.  Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals.

Authors:  D J Araten; K Nafa; K Pakdeesuwan; L Luzzatto
Journal:  Proc Natl Acad Sci U S A       Date:  1999-04-27       Impact factor: 11.205

2.  Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma.

Authors:  E Terpos; J Palermos; K Tsionos; K Anargyrou; N Viniou; P Papassavas; J Meletis; X Yataganas
Journal:  Eur J Haematol       Date:  2000-11       Impact factor: 2.997

3.  Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes.

Authors:  R E Ware; C V Pickens; C M DeCastro; T A Howard
Journal:  Exp Hematol       Date:  2001-12       Impact factor: 3.084

4.  Detection of "PNH red cell" populations in hematological disorders using the Sephacryl Gel Test micro typing system.

Authors:  J Meletis; E Michali; M Samarkos; K Konstantopoulos; C Meletis; E Terpos; A Tsimberidou; E Chandrinou; N Viniou; Y Rombos; G A Pangalis; X Yataganas; D Loukopoulos
Journal:  Leuk Lymphoma       Date:  1997-12

5.  Detection of CD55- and/or CD59-deficient red cell populations in patients with plasma cell dyscrasias.

Authors:  John Meletis; Evangelos Terpos; Michalis Samarkos; Christos Meletis; Effie Apostolidou; Veroniki Komninaka; Konstantinos Korovesis; Konstantinos Anargyrou; Olga Benopoulou; Despina Mavrogianni; Eleni Variami; Nora Viniou; Konstantinos Konstantopoulos
Journal:  Int J Hematol       Date:  2002-01       Impact factor: 2.490

6.  Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index.

Authors:  Evangelos Terpos; Richard Szydlo; Jane F Apperley; Evdoxia Hatjiharissi; Marianna Politou; John Meletis; Nora Viniou; Xenophon Yataganas; John M Goldman; Amin Rahemtulla
Journal:  Blood       Date:  2003-04-10       Impact factor: 22.113

7.  Detection of CD55- and/or CD59-deficient red cell populations in patients with lymphoproliferative syndromes.

Authors:  J Meletis; E Terpos; M Samarkos; C Meletis; E Apostolidou; V Komninaka; K Korovesis; D Mavrogianni; D Boutsis; E Variami; N Viniou; K Konstantopoulos; D Loukopoulos
Journal:  Hematol J       Date:  2001

8.  Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells.

Authors:  Therese Standal; Carina Seidel; Øyvind Hjertner; Torben Plesner; Ralph D Sanderson; Anders Waage; Magne Borset; Anders Sundan
Journal:  Blood       Date:  2002-10-15       Impact factor: 22.113

9.  Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure syndrome.

Authors:  Hongbo Wang; Tatsuya Chuhjo; Shizuka Yasue; Mitsuhiro Omine; Shinji Nakao
Journal:  Blood       Date:  2002-08-08       Impact factor: 22.113

10.  Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.

Authors:  M Hatanaka; T Seya; M Matsumoto; T Hara; M Nonaka; N Inoue; J Takeda; A Shimizu
Journal:  Biochem J       Date:  1996-03-15       Impact factor: 3.857

View more
  1 in total

1.  The presence of CD55- and/or CD59-deficient erythrocytic populations in patients with rheumatic diseases reflects an immune-mediated bone-marrow derived phenomenon.

Authors:  John V Asimakopoulos; Evangelos Terpos; Loula Papageorgiou; Olga Kampouropoulou; Dimitris Christoulas; Anastasios Giakoumis; Michael Samarkos; George Vaiopoulos; Konstantinos Konstantopoulos; Maria K Angelopoulou; Theodoros P Vassilakopoulos; John Meletis
Journal:  Med Sci Monit       Date:  2014-01-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.